80
Participants
Start Date
September 11, 2019
Primary Completion Date
December 20, 2021
Study Completion Date
October 26, 2022
Bavituximab
Bavituximab IV infusion
Pembrolizumab Injection
Pembrolizumab IV Infusion
National Cheng Kung University Hospital, Tainan City
White Plains Hospital - Center for Cancer Care, White Plains
Taipei Veterans General Hospital, Taipei
Seoul National University Bundang Hospital, Seongnam-si
Cancer Treatment Centers of America at Eastern Regional Medical Center, Philadelphia
Columbus Regional Research Institute, Columbus
Chang Gung Medical Foundation - Linkou Branch, Taoyuan District
Cleveland Clinic Florida - Weston, Weston
Sara Cannon Research Institute, Nashville
China Medical University Hospital, Taichung
UC Health Office of Clinical Research, Cincinnati
Dong-A University Hospital, Busan
The University of Chicago Medical Center, Chicago
Siteman Cancer Center - Washington University Medical Campus, St Louis
Smilow Cancer Hospital at Yale-New Haven, New Haven
Kyungpook National University Chilgok Hospital, Daegu
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
The Royal Marsden, London
Sarah Cannon Research Institute, London
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
OncXerna Theraputics, Inc.
INDUSTRY